More of the cancer patients who received CRISPR Therapeutics’ experimental, off-the-shelf CAR-T cell therapy showed complete remissions compared to the drug’s initial study results, according to a company update Tuesday. Some of the remissions are lasting six months or more, an important measure of durability.
In the CRISPR Therapeutics study, which remains preliminary, 24 adult patients with advanced B-cell lymphoma were injected with escalating doses of CTX110. Fourteen patients, or 58%, responded to treatment. Nine patients, or 38%, had complete responses, meaning tumor cells were no longer detectable.
The study results come at an uncertain time for companies using genome-editing technologies to develop more convenient cell treatments for cancer. Last week, Allogene’s off-the-shelf CAR-T programs were placed on clinical hold following the discovery of a “chromosomal abnormality” in a single patient treated with its therapy. The cause remains undetermined, although an investigation is underway.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
